DK2444505T3 - Urinmarkører til påvisning af blærecancer - Google Patents

Urinmarkører til påvisning af blærecancer

Info

Publication number
DK2444505T3
DK2444505T3 DK11188984.6T DK11188984T DK2444505T3 DK 2444505 T3 DK2444505 T3 DK 2444505T3 DK 11188984 T DK11188984 T DK 11188984T DK 2444505 T3 DK2444505 T3 DK 2444505T3
Authority
DK
Denmark
Prior art keywords
detection
bladder cancer
urinary markers
urinary
markers
Prior art date
Application number
DK11188984.6T
Other languages
English (en)
Inventor
Parry John Guilford
Natalie Jane Kerr
Robert Pollock
Original Assignee
Pacific Edge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Edge Ltd filed Critical Pacific Edge Ltd
Application granted granted Critical
Publication of DK2444505T3 publication Critical patent/DK2444505T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK11188984.6T 2004-07-23 2005-07-22 Urinmarkører til påvisning af blærecancer DK2444505T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ53428904 2004-07-23
NZ53921905 2005-04-04
US69261905P 2005-06-20 2005-06-20
EP05778290A EP1784503A4 (en) 2004-07-23 2005-07-22 URINARY MARKERS FOR DETECTING CANCER OF BLADDER

Publications (1)

Publication Number Publication Date
DK2444505T3 true DK2444505T3 (da) 2017-01-02

Family

ID=45755636

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11188984.6T DK2444505T3 (da) 2004-07-23 2005-07-22 Urinmarkører til påvisning af blærecancer
DK11188998.6T DK2434024T3 (da) 2004-07-23 2005-07-22 Urinmarkører til påvisning af blærecancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11188998.6T DK2434024T3 (da) 2004-07-23 2005-07-22 Urinmarkører til påvisning af blærecancer

Country Status (14)

Country Link
US (1) US11130789B2 (da)
EP (5) EP2434023B1 (da)
JP (6) JP5179177B2 (da)
KR (11) KR20120059648A (da)
CN (3) CN114250299A (da)
AU (1) AU2005266948A1 (da)
BR (2) BR122020001099B1 (da)
CA (5) CA2616277C (da)
DK (2) DK2444505T3 (da)
ES (4) ES2538504T3 (da)
NZ (2) NZ553297A (da)
PT (2) PT2444505T (da)
TW (4) TWI661199B (da)
WO (1) WO2006012522A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI661199B (zh) 2004-07-23 2019-06-01 太平洋愛吉生技股份有限公司 檢測膀胱癌之尿液標記物
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
ES2344932B1 (es) * 2009-02-10 2011-06-30 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe Metodo para la deteccion de cancer de vejiga.
US9315802B2 (en) 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
WO2012000976A1 (en) * 2010-07-02 2012-01-05 Topogen Inc. Method for diagnosis of bladder cancer and related kits
WO2012052844A1 (en) 2010-10-19 2012-04-26 Oslo Universitetssykehus Hf Methods and biomarkers for detection of bladder cancer
NZ589251A (en) * 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
US9663781B2 (en) 2010-12-30 2017-05-30 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
WO2013134693A1 (en) * 2012-03-09 2013-09-12 Insight Genetics, Inc. Methods and compositions relating to diagnosing and treating receptor tyrosine kinase related cancers
JP6175144B2 (ja) * 2012-12-04 2017-08-02 サイノファーム タイワン，リミティド 分子のプールの選択方法
CN103033625B (zh) * 2012-12-19 2014-12-24 中国科学院生物物理研究所 一种人膀胱癌细胞化学发光检测试剂盒及其制备方法
EP3339450A3 (en) * 2013-03-08 2018-08-08 MDxHealth Research B.V. Molecular markers in bladder cancer
CA2904126C (en) * 2013-03-08 2022-08-16 Noviogendix Research B.V. Molecular markers in bladder cancer
DE212013000295U1 (de) 2013-05-06 2016-02-02 Hitachi Chemical Co. America, Ltd. Vorrichtungen zum Einfangen von Zielmolekülen
PT3071973T (pt) * 2013-11-21 2021-01-13 Pacific Edge Ltd Triagem de pacientes com hematúria assintomática usando biomarcadores genotípicos e fenotípicos
CN105891500A (zh) * 2015-01-16 2016-08-24 刘晓强 一种快速检测膀胱癌的试纸
EP3304084B1 (en) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Methods and kits
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
JP6624704B2 (ja) * 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
RU2670655C2 (ru) * 2017-02-20 2018-10-24 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения Российской Федерации" Способ определения риска рецидива поверхностного рака мочевого пузыря после оперативного лечения
CN108866194B (zh) 2018-08-16 2021-03-26 杭州可帮基因科技有限公司 一组用于膀胱癌检测的基因及其应用
CN109055559A (zh) * 2018-09-28 2018-12-21 爱尔生基因医学科技有限公司 一种检测膀胱癌的特异性引物和试剂盒及其检测方法
CN109884301B (zh) * 2019-02-26 2023-03-31 上海市第十人民医院 一种用于肌层浸润性膀胱癌生存预后预测的生物标记物及其应用
JP2022553825A (ja) * 2019-10-31 2022-12-26 ショウワ デンコウ マテリアルズ（アメリカ），インコーポレイテッド 尿路上皮がん用の尿中ｅｖ ｒｎａバイオマーカー
EP4168125A1 (en) 2020-06-19 2023-04-26 Unilever IP Holdings B.V. A topical antimicrobial composition
RU2756255C1 (ru) * 2020-11-06 2021-09-28 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого" Министерства Здравоохранения Российской Федерации Способ раннего выявления рака мочевого пузыря с помощью цитофлоуриметрического анализа клеточного осадка мочи
CN114686607B (zh) * 2020-12-31 2023-09-26 深圳华大生命科学研究院 棒状杆菌作为尿液微生物标志物在制备用于检测膀胱癌的相关检测产品中的应用
KR102632423B1 (ko) * 2021-02-26 2024-01-31 충북대학교 산학협력단 비근침윤성 방광암의 예후 예측을 위한 바이오마커 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
AUPN245295A0 (en) * 1995-04-13 1995-05-11 Johnson & Johnson Research Pty. Limited Assay for genetic abnormalities
DK0932678T4 (da) 1996-09-24 2010-07-12 Genentech Inc En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåder til anvendelse deraf
US6495532B1 (en) 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6492144B1 (en) 1997-05-30 2002-12-10 Diagen Corporation Methods for detection of nucleic acid sequences in urine
ES2355631T3 (es) 1997-05-30 2011-03-29 Trovagene, Inc. Procedimiento para detectar secuencias de ácidos nucleicos en la orina.
WO1999064627A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
CA2375467C (en) * 1999-07-19 2013-10-29 The University Of British Columbia Antisense therapy for hormone-regulated tumors
IL148798A0 (en) 1999-09-27 2002-09-12 Quark Biotech Inc Sequences characteristic of bladder cancer
US6419896B1 (en) 2000-03-03 2002-07-16 Bert Vogelstein Non-invasive approach for assessing tumors in living animals
IT1318504B1 (it) * 2000-05-08 2003-08-27 Talent Srl Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina.
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
CA2320549A1 (en) 2000-09-25 2002-03-25 Eastern Virginia Medical College Biomarkers of transitional cell carcinoma of the bladder
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
WO2002103320A2 (en) 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
EP1285970A3 (en) 2001-06-26 2004-05-19 National Taiwan University Metastasis-associated genes
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030113758A1 (en) * 2001-08-14 2003-06-19 Pierre Oudet Method for the in vitro diagnosis of a predisposition to bladder cancer or of the occurrence of bladder cancer and a kit for performing said diagnostic method
US20040043436A1 (en) * 2001-09-21 2004-03-04 Antonia Vlahou Biomarkers of transitional cell carcinoma of the bladder
JP2003279578A (ja) * 2002-03-26 2003-10-02 National Shikoku Cancer Center 癌の診断支援方法及びそのキット
US20050032065A1 (en) 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
AU2003258426B2 (en) * 2002-08-21 2008-04-10 The University Of British Columbia RNAi probes targeting cancer-related proteins
US7217515B2 (en) * 2002-09-30 2007-05-15 Chi Mei Foundation Medical Center HURP gene as a molecular marker for bladder cancer
AU2003275546A1 (en) 2002-10-08 2004-05-04 Denki Kagaku Kogyo Kabushiki Kaisha Heat-schrinkable film
AU2003275946A1 (en) * 2002-11-01 2004-05-25 Aros Applied Biotechnology Aps Gene expression in biological conditions
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
TWI661199B (zh) 2004-07-23 2019-06-01 太平洋愛吉生技股份有限公司 檢測膀胱癌之尿液標記物
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer

Also Published As

Publication number Publication date
KR20220116354A (ko) 2022-08-22
CN101027412B (zh) 2017-04-26
AU2005266948A1 (en) 2006-02-02
EP2434024B1 (en) 2016-09-07
BR122020001099B1 (pt) 2021-12-14
TWI540321B (zh) 2016-07-01
CA2616277C (en) 2023-03-07
KR20180023048A (ko) 2018-03-06
KR20220012933A (ko) 2022-02-04
JP2017104118A (ja) 2017-06-15
BRPI0513692B1 (pt) 2020-11-10
BRPI0513692B8 (pt) 2021-07-27
KR20220012881A (ko) 2022-02-04
CN107326066A (zh) 2017-11-07
NZ595684A (en) 2013-06-28
EP2444505A3 (en) 2012-07-18
KR20070051286A (ko) 2007-05-17
CA3147181A1 (en) 2006-02-02
EP2444505A2 (en) 2012-04-25
ES2612197T3 (es) 2017-05-12
TWI503416B (zh) 2015-10-11
JP2012185173A (ja) 2012-09-27
JP5179177B2 (ja) 2013-04-10
KR20130137054A (ko) 2013-12-13
ES2612482T3 (es) 2017-05-17
US20100273148A1 (en) 2010-10-28
CA3147162A1 (en) 2006-02-02
KR20160105914A (ko) 2016-09-07
DK2434024T3 (da) 2017-01-02
JP6309594B2 (ja) 2018-04-11
JP2008507558A (ja) 2008-03-13
NZ553297A (en) 2010-10-29
EP1784503A4 (en) 2009-08-12
JP6248297B2 (ja) 2017-12-20
PT2444505T (pt) 2017-01-13
BRPI0513692A (pt) 2008-05-13
PT2434024T (pt) 2017-01-13
TW201525463A (zh) 2015-07-01
EP2436779B1 (en) 2015-03-25
JP6670774B2 (ja) 2020-03-25
JP2015156866A (ja) 2015-09-03
KR20130027059A (ko) 2013-03-14
CA2862993A1 (en) 2006-02-02
EP2436779A1 (en) 2012-04-04
CA2616277A1 (en) 2006-02-02
CN101027412A (zh) 2007-08-29
ES2538504T3 (es) 2015-06-22
EP2434023A1 (en) 2012-03-28
KR20220012993A (ko) 2022-02-04
CN114250299A (zh) 2022-03-29
JP2017060489A (ja) 2017-03-30
KR20140122285A (ko) 2014-10-17
KR101652854B1 (ko) 2016-08-31
CA2862993C (en) 2019-01-15
KR101514582B1 (ko) 2015-05-04
US11130789B2 (en) 2021-09-28
TWI585411B (zh) 2017-06-01
KR20120059648A (ko) 2012-06-08
TW201734454A (zh) 2017-10-01
TW201217787A (en) 2012-05-01
TWI661199B (zh) 2019-06-01
CN107326066B (zh) 2021-10-26
EP2444505B1 (en) 2016-09-07
CA3147177A1 (en) 2006-02-02
EP2434024A1 (en) 2012-03-28
JP6174303B2 (ja) 2017-08-02
WO2006012522A1 (en) 2006-02-02
JP2018183162A (ja) 2018-11-22
EP2434023B1 (en) 2015-02-25
EP1784503A1 (en) 2007-05-16
ES2540108T3 (es) 2015-07-08

Similar Documents

Publication Publication Date Title
DK2444505T3 (da) Urinmarkører til påvisning af blærecancer
DK2407201T3 (da) Teleskopkateter til mænd
DK2279767T3 (da) Urinvejskateter
ATE429585T1 (de) Rohrleitung
DK1809978T3 (da) Modul-skydebane
DE502005010217D1 (de) Einparkhilfe
PL2198042T3 (pl) Nowe markery do wykrywania raka pęcherza moczowego
ATE419540T1 (de) Blitzerkennung
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
DK1954834T3 (da) Brystcancermarkører
BRPI0811277A2 (pt) Detecção de marcadores de câncer
DK3326681T3 (da) Indretning til behandling af analsphincteren
GB0421838D0 (en) Cancer markers
DK1784181T3 (da) VEGF-hæmning
NO20043033L (no) Rorplassering
DE502005007528D1 (de) Hyrdodynamische kupplung
NO20072717L (no) Sporingsanordning
ATE365231T1 (de) Abstichrohr
ATA12632004A (de) Stelleinrichtung
NL1027229A1 (nl) Markeerinrichting.
ATA12642004A (de) Stelleinrichtung
ATA9992004A (de) Hydrant
FI20041703A0 (fi) Sektoriloisto
FI20045024A0 (fi) Toroidimainen kuristin
ES1058861Y (es) Urinario retraible